Rin Nakamura

TL;DR: The potential for the anti-FcRH5/CD3 TDB, alone or in combination with inhibition of PD-1/PD-L1 signaling, in the treatment of MM and other B cell malignancies is demonstrated.

TL;DR: The results suggest that the anatomic location of metastases and time of collection may influence the detection of PD-L1, which was highest in lymph nodes and lowest in liver metastases while breast tissue was intermediate.

TL;DR: Evaluation of expression of TIGIT, CD226, PD-1 and PD-L1 in patients with MM to inform novel immunotherapy combinations finds additional benefit of TigIT blockade through elaboration of CD226-mediated anti-tumor immunity, analogous to CTLA-4/CD28 regulation of T-cell immunity.

TL;DR: Preliminary biomarker data are presented that demonstrate the mode of action (MOA) of BFCR4350A, provide support for Cycle (C) 1 step-up dosing, and offer preliminary insights into markers that may predict response.

TL;DR: In this article, gene expression analyses of metastatic urothelial bladder cancer (UBC) patients were conducted to interrogate the tumor immune microenvironment in PD-L1-positive tumors and to identify potential mechanisms associated with response or resistance to MPDL3280A.